Skip to main content
OMI
NYSE Trade & Services

Accendra Health Files Pro Forma Financials for $375M P&HS Business Sale and $280M Debt Repayment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
9
Price
$2.86
Mkt Cap
$216.57M
52W Low
0
52W High
0
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Accendra Health filed an amended 8-K to provide pro forma financial statements detailing the impact of its $375 million sale of the Products & Healthcare Services (P&HS) business and the subsequent repayment of $280 million in long-term debt.


Key Events · M&A and Partnerships · OMI

  • Pro Forma Financials Filed

    Accendra Health filed an 8-K/A to include unaudited pro forma condensed consolidated financial statements, which are essential for investors to assess the company's post-transaction financial state.

  • P&HS Business Divestiture

    The pro forma financials reflect the completion of the sale of the Products & Healthcare Services (P&HS) business for $375 million in cash. Accendra Health retained a 5% non-voting equity interest in the buyer.

  • Debt Repayment

    Proceeds from the P&HS business sale are anticipated to be used to repay $280 million of the current portion of the company's long-term debt, which will reduce financial leverage.

  • Receivables Program Amendment

    The Receivables Sale Program was amended, involving the sale of $94 million in eligible receivables and the removal of a $160 million intercompany payable related to the P&HS accounts receivable.


Analysis · OMI · Trade & Services

This amended filing is critical for investors as it provides the unaudited pro forma financial statements necessary to understand Accendra Health's financial position and operating results following the significant divestiture of its Products & Healthcare Services (P&HS) business. The sale, valued at $375 million, represents a substantial restructuring for the company. The anticipated use of proceeds to repay $280 million of current long-term debt is a positive step, significantly reducing the company's financial leverage and interest expense. Investors should analyze these pro forma financials to re-evaluate the company's future revenue, profitability, and balance sheet strength in its streamlined form.

At the time of this filing, OMI was trading at $2.86 on NYSE in the Trade & Services sector, with a market capitalization of approximately $216.6M. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OMI - Latest Insights